NOVOZYMES -B-
NOVOZYMES -B- operates in Diversified Metals & Mining.
NOVOZYMES -B- (NZM2) - Net Assets
Latest net assets as of December 2023: €14.35 Billion EUR
Based on the latest financial reports, NOVOZYMES -B- (NZM2) has net assets worth €14.35 Billion EUR as of December 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€28.39 Billion) and total liabilities (€14.04 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €14.35 Billion |
| % of Total Assets | 50.55% |
| Annual Growth Rate | 2.9% |
| 5-Year Change | 25.01% |
| 10-Year Change | N/A |
| Growth Volatility | 6.59 |
NOVOZYMES -B- - Net Assets Trend (2016–2023)
This chart illustrates how NOVOZYMES -B-'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NOVOZYMES -B- (2016–2023)
The table below shows the annual net assets of NOVOZYMES -B- from 2016 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €14.35 Billion | +0.86% |
| 2022-12-31 | €14.23 Billion | +16.57% |
| 2021-12-31 | €12.21 Billion | +8.56% |
| 2020-12-31 | €11.24 Billion | -2.06% |
| 2019-12-31 | €11.48 Billion | +0.37% |
| 2018-12-31 | €11.44 Billion | +1.52% |
| 2017-12-31 | €11.27 Billion | -4.07% |
| 2016-12-31 | €11.74 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to NOVOZYMES -B-'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 31.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €13.76 Billion | 98.40% |
| Other Components | €223.00 Million | 1.60% |
| Total Equity | €13.98 Billion | 100.00% |
NOVOZYMES -B- Competitors by Market Cap
The table below lists competitors of NOVOZYMES -B- ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ASA GOLD+PREC.MET.LTD.DL1
F:FZ6
|
$531.01K |
|
Worlds Inc
OTCQB:WDDD
|
$531.15K |
|
SALAFIN
BC:SALAFIN
|
$531.38K |
|
Taiwan Taomee Co. Ltd.
TWO:6428
|
$531.50K |
|
AMADEUS IT HOLD -A- - Dusseldorf Stock Exchang
DU:AI3A
|
$530.63K |
|
PC CONNECTION
MU:PCC
|
$530.19K |
|
BOLT BIOTHERAP. DL-00001
F:6LP
|
$529.61K |
|
Gentor Resources Inc
PINK:GNTOF
|
$529.23K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NOVOZYMES -B-'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 13,837,000,000 to 13,978,000,000, a change of 141,000,000 (1.0%).
- Net income of 3,024,000,000 contributed positively to equity growth.
- Dividend payments of 2,856,000,000 reduced retained earnings.
- New share issuances of 167,000,000 increased equity.
- Other factors decreased equity by 194,000,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €3.02 Billion | +21.63% |
| Dividends Paid | €2.86 Billion | -20.43% |
| Share Issuances | €167.00 Million | +1.19% |
| Other Changes | €-194.00 Million | -1.39% |
| Total Change | €- | 1.02% |
Book Value vs Market Value Analysis
This analysis compares NOVOZYMES -B-'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.08x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.42x to 1.08x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €38.42 | €54.62 | x |
| 2018-12-31 | €39.73 | €54.62 | x |
| 2019-12-31 | €40.76 | €54.62 | x |
| 2020-12-31 | €40.21 | €54.62 | x |
| 2021-12-31 | €42.68 | €54.62 | x |
| 2022-12-31 | €50.03 | €54.62 | x |
| 2023-12-31 | €50.40 | €54.62 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NOVOZYMES -B- utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 21.63%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.89%
- • Asset Turnover: 0.63x
- • Equity Multiplier: 2.03x
- Recent ROE (21.63%) is below the historical average (26.18%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 26.00% | 21.57% | 0.76x | 1.59x | €1.88 Billion |
| 2017 | 27.71% | 21.46% | 0.79x | 1.63x | €1.99 Billion |
| 2018 | 28.24% | 22.42% | 0.73x | 1.72x | €2.08 Billion |
| 2019 | 27.50% | 21.94% | 0.70x | 1.78x | €2.01 Billion |
| 2020 | 25.15% | 20.16% | 0.68x | 1.83x | €1.70 Billion |
| 2021 | 26.60% | 21.04% | 0.60x | 2.09x | €1.96 Billion |
| 2022 | 26.57% | 20.94% | 0.63x | 2.02x | €2.29 Billion |
| 2023 | 21.63% | 16.89% | 0.63x | 2.03x | €1.63 Billion |
Industry Comparison
This section compares NOVOZYMES -B-'s net assets metrics with peer companies in the Other industry.
Industry Context
- Industry: Other
- Average net assets among peers: $114,212,818,724
- Average return on equity (ROE) among peers: -9.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NOVOZYMES -B- (NZM2) | €14.35 Billion | 26.00% | 0.98x | $530.78K |
| HORIBA (01H) | $204.49 Billion | 10.42% | 0.82x | $989.01K |
| Tokyu Corporation (01T) | $779.37 Billion | 3.34% | 2.35x | $99.73K |
| GUANGZHOU AUTO -H- (02G) | $122.28 Billion | 6.59% | 0.55x | $4.05K |
| MOSAIC (02M) | $10.60 Billion | 4.43% | 0.90x | $280.83K |
| MOSAIC (02M.SG) (02M) | $9.56 Billion | 10.46% | 0.82x | $247.21K |
| CHINA JO-JO DRGSTRS (04CN.SG) (04CN) | $16.67 Million | -126.83% | 4.46x | $1.55 Million |
| KRAKATAU STEEL -B- (07K) | $552.59 Million | 3.52% | 4.72x | $166.99 |
| CN MODERN DAIRY (07M) | $7.12 Billion | -10.42% | 1.50x | $1.68K |
| TOURMALINE OIL (08T) | $7.22 Billion | 4.81% | 0.41x | $381.02K |
| ASIA CASSAVA RESOUR (0ACS) | $913.15 Million | 2.86% | 1.55x | $325.03 |